Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1461. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan

for colorecteral cancer in a high risk population. Annals of Internal Medicine 1990;13:373-84. Okubo I, Glick HA, Frumkin H, et al. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991;67:2021-9. Indexing Status Subject indexing assigned by NLM MeSH Adult; Colorectal Neoplasms /diagnosis /economics; Cost-Benefit Analysis; Female; Humans; Japan; Male; Mass Screening /economics; Sensitivity and Specificity AccessionNumber 22005008034 Date bibliographic record published 28/02/2005 (...) Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan Shimbo T, Glick H A, Eisenberg J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

1994 NHS Economic Evaluation Database.

1462. Should relatives of patients with colorectal cancer be screened: a critical review of the literature

there are no studies that document decreased overall mortality from CRC in first-degree relatives as a result of screening, the decision as to whether to screen this population needs to be based on future prospective controlled trials and these must be standardised. Bibliographic details Brewer D A, Fung C L, Chapuis P H, Bokey E L. Should relatives of patients with colorectal cancer be screened: a critical review of the literature. Diseases of the Colon and Rectum 1994; 37(12): 1328-1338 PubMedID Indexing Status (...) Should relatives of patients with colorectal cancer be screened: a critical review of the literature Should relatives of patients with colorectal cancer be screened: a critical review of the literature Should relatives of patients with colorectal cancer be screened: a critical review of the literature Brewer D A, Fung C L, Chapuis P H, Bokey E L Authors' objectives To assess whether there should be index screening and surveillance of relatives of patients with colorectal cancer (CRC). Searching

1994 DARE.

1463. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Full Text available with Trip Pro

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. To compare the length of survival and quality of life in patients given combination chemotherapy in addition to supportive care and in patients given only supportive care.Randomised study.Gastrointestinal oncology departments.40 previously untreated patients with histologically confirmed, measurable colorectal cancer that was locally recurrent (...) functional living index-cancer scale.Overall survival was significantly longer for patients given chemotherapy (11.0 months) than for those receiving supportive care alone (5.0 months; p = 0.006). Despite common association of chemotherapy with mild to moderate gastrointestinal symptoms, there was no significant difference between the two groups in global or subgroup quality of life scores. In patients with abnormal scores before treatment, quality of life seemed better in the chemotherapy arm.In

1993 BMJ Controlled trial quality: uncertain

1464. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. (Abstract)

Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Homologous blood transfusion has been associated with an increased risk of postoperative infectious complications. To test the clinical consequences of this apparently immunosuppressive effect of homologous blood in a controlled trial, we designed a study in which the control group deposited autologous blood before their operations for use should transfusion be needed. We enrolled 120 (...) patients with apparently curable colorectal cancer who were able to predeposit autologous blood (haemoglobin > 12.5 g/dL). 62 patients were assigned to receive homologous blood if blood transfusions were needed during operation, and the other 58 to receive their own predeposited blood followed, if necessary, by homologous blood [corrected]. Despite the similarity between the groups in factors known to affect the risk of postoperative infections, there was a significant difference in postoperative

1993 Lancet Controlled trial quality: uncertain

1465. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. Full Text available with Trip Pro

Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. Although tests for occult blood in the feces are widely used to screen for colorectal cancers, there is no conclusive evidence that they reduce mortality from this cause. We evaluated a fecal occult-blood test in a randomized trial and documented its effectiveness.We randomly assigned 46,551 participants 50 to 80 years of age to screening for colorectal cancer once a year (...) specimen. Differences in mortality from colorectal cancer, the primary study end point, were monitored with the sequential log-rank statistic.The 13-year cumulative mortality per 1000 from colorectal cancer was 5.88 in the annually screened group (95 percent confidence interval, 4.61 to 7.15), 8.33 in the biennially screened group (95 percent confidence interval, 6.82 to 9.84), and 8.83 in the control group (95 percent confidence interval, 7.26 to 10.40). The rate in the annually screened group

1993 NEJM Controlled trial quality: uncertain

1466. Blood transfusions and prognosis in colorectal cancer. (Abstract)

Blood transfusions and prognosis in colorectal cancer. Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported.We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group (...) were required to donate two units of blood before surgery.A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those

1993 NEJM Controlled trial quality: uncertain

1467. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. (Abstract)

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. About half the patients treated with curative resection for colorectal cancer do not survive long-term. Adjuvant chemotherapy given during and after surgery may prevent hepatic metastases and improve patient survival. In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion (...) % compared with surgery-only controls. Further study of intraportal infusion of chemotherapeutic agent as adjuvant treatment to surgery in patients with colorectal cancer appears worthwhile.

1992 Lancet Controlled trial quality: uncertain

1468. Filtering strategies in mass population screening for colorectal cancer: an economic evaluation

of related interest Hardcastle JD, Thomase WM, Chamberlain J, et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer: results for the first 107,344 patients. Lancet 1989;i:119-23. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /epidemiology /prevention & Cost-Benefit Analysis; Costs and Cost Analysis; Humans; Mass Screening /economics /methods /standards; Models, Econometric; Occult Blood; Patient Compliance; Prevalence; Sensitivity (...) Filtering strategies in mass population screening for colorectal cancer: an economic evaluation Filtering strategies in mass population screening for colorectal cancer: an economic evaluation Filtering strategies in mass population screening for colorectal cancer: an economic evaluation Walker A, Whynes D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results

1992 NHS Economic Evaluation Database.

1469. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. (Abstract)

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. Twelve hundred ninety-six patients with resected colon cancer that either was locally invasive (Stage B2) or had regional nodal involvement (Stage C) were randomly assigned to observation or to treatment for one year with levamisole combined with fluorouracil. Patients with Stage C disease could also be randomly assigned to treatment with levamisole alone. The median follow-up time at this writing is 3 years (range, 2 (...) to 5 1/2). Among the patients with Stage C disease, therapy with levamisole plus fluorouracil reduced the risk of cancer recurrence by 41 percent (P less than 0.0001). The overall death rate was reduced by 33 percent (P approximately 0.006). Treatment with levamisole alone had no detectable effect. The results in the patients with Stage B2 disease were equivocal and too preliminary to allow firm conclusions. Toxic effects of levamisole alone were infrequent, usually consisting of mild nausea

1990 NEJM Controlled trial quality: uncertain

1470. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. (Abstract)

Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. To assess the effectiveness of screening by faecal occult blood tests, 107,349 people without symptoms of colorectal disease identified from general practitioner records have been randomly allocated to test and control groups. 53,464 test subjects were invited to carry out the screening test; 27,651 (53%) of the 52,258 who received the tests did so. Further investigation (...) A) was 0.72 per 1000 person-years. Cancers detected by screening were at a less advanced pathological stage, but it is too early to show any effect of screening on mortality from colorectal cancer.

1989 Lancet Controlled trial quality: uncertain

1471. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. (Abstract)

Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative (...) radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients). Five years after the entry of the last patient and with a median follow-up of all survivors for 80 months, the recurrence rate was highest among the control patients (55 per cent) and lowest among the patients receiving a combination of adjuvant radiation and chemotherapy (33 per cent). Time to tumor

1985 NEJM Controlled trial quality: uncertain

1472. Cost benefits of hemoccult screening for colorectal carcinoma

screening for colorectal carcinoma. Digestive Diseases and Sciences 1985; 30(9): 860-865 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Colonic Neoplasms /epidemiology; Cost-Benefit Analysis; Humans; Mass Screening /economics; Middle Aged; Occult Blood; Reagent Kits, Diagnostic /economics; Rectal Neoplasms /epidemiology AccessionNumber 21995005293 Date bibliographic record published 25/06/1996 Date abstract record published 25/06/1996 NHS Economic Evaluation Database (NHS EED (...) Cost benefits of hemoccult screening for colorectal carcinoma Cost benefits of hemoccult screening for colorectal carcinoma Cost benefits of hemoccult screening for colorectal carcinoma Allison J E, Feldman R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

1985 NHS Economic Evaluation Database.

1473. Adjuvant therapy of colon cancer--results of a prospectively randomized trial. Gastrointestinal Tumor Study Group. (Abstract)

Adjuvant therapy of colon cancer--results of a prospectively randomized trial. Gastrointestinal Tumor Study Group. After curative surgical resection, 621 patients with modified Dukes' stage B2, C1, or C2 colon carcinoma were randomly assigned to one of four treatment programs. These included chemotherapy with fluorouracil and semustine, immunotherapy with methanol extraction residue of bacillus Calmette-Guérin (BCG), combination therapy with fluorouracil, semustine, and immunotherapy, or close (...) as an adjuvant treatment program for patients at high risk for recurrent colon carcinoma. The data do, however, demonstrate the necessity for an untreated control group in a trial of adjuvant therapy for colon cancer.

1984 NEJM Controlled trial quality: uncertain

1474. Controlled trial of faecal occult blood testing in the detection of colorectal cancer. (Abstract)

. 77 people (2 . 1%) had a positive test result, and 50% of these on investigation had neoplastic disease--12 had invasive carcinomas (9 Dukes' stage A, 2 stage B, 1 stage C) and 27 had 40 adenomas (12 over 2 cm, 2 of which contained areas of severe dysplasia). In the year following the screening test 1 carcinoma (stage C) has presented in the group which accepted the test, and 10 carcinomas (4 stage B, 4 stage C, 2 stage D) have presented in the control group. This respresents a 3 . 6 times (...) Controlled trial of faecal occult blood testing in the detection of colorectal cancer. 20 525 patients from general practitioners' lists were randomly allocated into test and control groups. The 10 253 test subjects were invited to perform haemoccult faecal occult blood testing over 3 days. 3613 (36 . 8%) of the 9807 who received their invitations completed the test. Compliance was improved by direct invitation from the general practitioner and by prior health education by letter or interview

1983 Lancet Controlled trial quality: uncertain

1475. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). (Abstract)

Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). We evaluated the risk of acute nonlymphocytic leukemia, acute myelodysplastic syndrome, and preleukemia in 3633 patients with gastrointestinal cancer who were treated in nine randomized clinical trials. Among 2067 patients given semustine (methyl-CCNU) as adjuvant therapy, leukemic disorders developed in 14, whereas only one leukemic disorder (acute nonlymphocytic leukemia) occurred among (...) radiotherapy or immunotherapy. In addition, no excess of acute nonlymphocytic leukemia was seen in 44,370 patients treated for gastrointestinal cancer in Connecticut during the period 1935 to 1974, before the advent of nitrosourea chemotherapy. This study provides quantitative evidence that nitrosoureas are leukemogenic in human beings and confirms previous observations that adjuvant chemotherapy with alkylating agents may increase the risk of leukemia.

1983 NEJM Controlled trial quality: uncertain

1476. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. (Abstract)

Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. A phase-I clinical trial of a murine monoclonal antibody that specifically suppresses growth of human gastrointestinal tumours in athymic mice was conducted in four patients, who were given 15-200 mg purified antibody. The monoclonal antibody persisted in the circulation for more than a week when more than 15 mg was given. Antibodies against mouse immunoglobulin developed in three of the four patients

1982 Lancet

1477. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. (Abstract)

Preoperative parenteral feeding in patients with gastrointestinal carcinoma. In a comparative clinical trial to examine the influence of 10 days of preoperative parenteral nutrition (PPN) on the postoperative complication rate for gastrointestinal carcinoma 59 patients (controls) received the regular hospital diet and 66 received PPN. The two groups were similar in nutritional status and in distribution of site and stage of tumour and type of operation. The rates of postoperative wound

1982 Lancet Controlled trial quality: uncertain

1478. Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil. (Abstract)

Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil. 83 patients with colorectal carcinoma of the Dukes' C class were randomised to receive postoperative adjuvant therapy with B.C.G. alone or in combination with oral doses of 5-fluorouracil (5-F.U.), and have been followed for up to thirty months. Results were compared with carefully selected historical controls who were treated by surgery alone. A statistically (...) significant prolongation of both disease-free interval and overall survival was observed in 50 patients receiving the combination of B.C.G. and 5-F.U. (P=0.03, P=0.01 respectively) as well as in 33 patients receiving B.C.G. alone (P=0.03, P=0.05 respectively). The efficacy of B.C.G.+5-F.U. was independent of the number of tumour-involved lymph-nodes in the surgical specimen. In contrast, B.C.G. given alone appears to be highly effective among 10 patients with 6 or more positive lymph-nodes (P less than

1976 Lancet